Modulation of effect of dietary salt on prehepatic first-pass metabolism: Effects of β-blockade and intravenous salt loading

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 1, 1999, Pages 253-258

  Fromm, Martin F ^a   Darbar, Dawood ^a   Dell'Orto, Simonetta ^a   Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NADOLOL; QUINIDINE; SODIUM CHLORIDE;

ADULT; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; FIRST PASS EFFECT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SALT INTAKE; SALT LOADING; SODIUM RESTRICTION;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTI-ARRHYTHMIA AGENTS; DIET, SODIUM-RESTRICTED; EXERCISE TEST; FEMALE; HALF-LIFE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER; MALE; NADOLOL; QUINIDINE; SODIUM; SODIUM, DIETARY; TISSUE DISTRIBUTION;

EID: 0033045411     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. 2-adrenergic receptors. Surgery 110:1132-1138.
2. Bellet S, Roman LR and Boza A (1971) Relation between serum quinidine levels and renal function: Studies in normal subjects and patients with congestive failure and renal insufficiency. Am J Cardiol 27:368-371.
3. Bruce RA, Kusumi F and Hosmer D (1973) Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. Am Heart J 85:546-562.
4. Brunsson I, Fahrenkrug J, Jodal M, Sjöqvist A and Lundgren O (1995) Substance P effects on blood flow, fluid transport and vasoactive intestinal polypeptide release in the feline small intestine. J Physiol 483.3:727-734.
5. Darbar D, Dell'Orto S, Morike K, Wilkinson GR and Roden DM (1997) Dietary salt increases first-pass elimination of oral quinidine. Clin Pharmacol Ther 61:292-300.
6. Darbar D, Dell'Orto S, Wilkinson GR and Roden DM (1996) Loss of quinidine gluconate to plastic intravenous infusion sets. Am J Health System Pharmacy 53:655-658.
7. Darbar D, Fromm MF, Dell'Orto S, Kim RB, Kroemer HK, Eichelbaum M and Roden DM (1998) Modulation by dietary salt of verapamil disposition in humans. Circulation 98:2702-2708.
8. Fraser J, Nadeau JHJ, Robertson DH and Wood AJJ (1981) Regulation of human leucocyte beta receptors by endogenous catecholamines: Relationship of leucocyte beta receptor density to the cardiac sensitivity to isoproterenol. J Clin Invest 67:1777-1784.
9. Fromm MF, Kim RB, Stein CM, Wilkinson GR and Roden DM (1999) Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99:552-557.
10. Gatmaitan ZC and Arias IM (1993) Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol 24:77-97.
11. Gillis AM, Mitchell LB, Wyse DG, McDonald M and Duff HJ (1995) Quinidine pharmacodynamics in patients with arrhythmia: Effects of left ventricular function. J Am Coll Cardiol 25:989-994.
12. Guengerich FP, Müller-Enoch and Blair IA (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30:287-295.
13. Higgins CF (1995) The ABC of channel regulation. Cell 82:693-696.
14. Karlsson J, Kuo SH, Ziemniak J and Artursson P (1993) Transport of celiprolol across human intestinal epithelial (Caco-2) cells: Mediation of secretion by multiple transporters including P-glycoprotsin. Br J Pharmacol 110:1009-1016.
15. Kates RE, McKennon DW and Comstock TJ (1978) Rapid high-pressure liquid chromatographic determination of quinidine and dihydroquinidine in plasma samples. J Pharm Sci 67:269-270.
16. Kessler KM, Lowenthal DT, Warner H, Gibson T, Briggs W and Reidenberg MM (1974) Quinidine elimination in patients with congestive heart failure or poor renal function. N Engl J Med 290:706-709.
17. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM and Wilkinson GR (1998) P-glycoprotein transporter limits oral absorption and brain entry of HIV protease inhibitors. J Clin Invest 101:289-294.
18. Kivistö KT, Kroemer HK and Eichelbaum M (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions. Br J Clin Pharmacol 40:523-530.
19. Kolars JC, Schmiedlin-Ren P, Dobbins WO3, Schuetz J, Wrighton SA and Watkins PB (1992) Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 102:1186-1198.
20. Levens NR (1985) Control of intestinal absorption by the renin-angiotensin system. Am J Physiol 249:G3-G15.
21. Levens NR (1986) Response of isolated rat jejunum to angiotensin peptides. Am J Physiol 261:G559-G566.
22. Levens NR, Munday KA, Parsons BJ, Poat JA and Stewart CP (1979) Noradrenaline as a possible mediator of the actions of angiotensin on fluid transport by rat jejunum in vivo. J Physiol 286:351-360.
23. Levêque D and Jehl F (1995) P-glycoprotein and pharmacokinetics. Anticancer Res 15:331-336.
24. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo WS and Watkins PB (1997) Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99:2545-2553.
25. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA and Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22:947-955.
26. Pinedo HM and Giaccone G (1995) P-glycoprotein: A marker of cancer-cell behavior. N Engl J Med 333:1417-1419.
27. Schinkel AH, Wagenaar E, van Deemter L, Mol CAAM and Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
28. Schmiedlin-Ren P, Edwards DJ, Fitzsimmonis ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF and Watkins PB (1997) Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 25:1228-1233.
29. Sjövall H (1984) Sympathetic control of jejunal fluid and electrolyte transport: An experimental study in cats and rats. Acta Physiol Scand (Suppl) 535:1-63.
30. Terao T, Hisanaga E, Sai Y, Tamai I and Tsuji A (1996) Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 48:1083-1089.
31. Thiebaut F, Tsuruo T, Hamada H, Gotteeman MM, Pastan I and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
32. Thompson (Murray) KA, Blair IA, Woosley RL and Roden DM (1987) Comparative in vitro electrophysiology of quinidine, its major metabolites and dihydroquinidine. J Pharmacol Exp Ther 241:84-90.
33. Ueda CT and Dzindzio BS (1978) Quinidine kinetics in congestive heart failure. Clin Pharmacol Ther 23:158-164.
34. Wacher VJ, Wu CY and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogen 13:129-134.
35. Walter-Sack I and Klotz U (1996) Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 31:47-64.
36. Watkins PB (1997) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Del Rev 27:161-170.
37. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT and Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029-1036.
38. Wilkinson GR (1997) The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv Drug Del Rev 27:129-159.